Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Proceeds to fund global Phase 3 registration program for the company’s lead product candidate, Obexelimab, and support the clinical development of other pipeline programs

Series B equity financing led by Enavate Sciences, a portfolio company of Patient Square Capital, also included new investors Longitude Capital and Vivo Capital

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced proceeds of $118 million in connection with the issuance of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor, Inc. also participated in the financing, which included the infusion of new capital as well as the conversion of convertible notes issued to certain of the investors in advance of the closing of the Series B financing.

Proceeds from the financing will support the clinical advancement of the company’s lead product candidate Obexelimab, including a global Phase 3 registration trial in patients with IgG4-related disease (IgG4-RD), which will be initiated in late 2022. In addition, the new funding will progress the company’s other global autoimmune disease programs into clinical development in 2023.

“We are thrilled to support Zenas as an innovative leader in biotechnology as the team executes the clinical development plans for IgG4-RD and the robust pipeline of immune-based therapies so adeptly acquired through strategic business development. We believe Zenas will successfully commercialize innovative therapies to improve the lives of those facing autoimmune and rare diseases,” said James Boylan, Chief Executive Officer of Enavate Sciences.

“We are thrilled to have the support of Enavate and this top-tier group of global investors as we continue to advance our deep and balanced pipeline of clinical stage autoimmune therapeutics and execute our successful business development strategy,” said Lonnie Moulder, Founder and Executive Chairman of Zenas BioPharma.

In connection with the Series B financing, Enavate Sciences CEO Jim Boylan, Longitude Capital Co-founder and Managing Director Patrick Enright, and Vivo Capital Managing Partner Hongbo Lu have joined the Zenas Board of Directors.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

About Obexelimab

Obexelimab (ZB012), is an investigational phase III-stage, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Simultaneous binding to CD19 and FcƳRIIB by obexelimab mimics a natural antigen-antibody complex and down-regulates B-cell activity. In early-stage clinical studies, obexelimab effectively demonstrated inhibition of B-cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.

About IgG4-RD

IgG4-RD is a chronic and serious, fibroinflammatory disease typically affecting multiple organs and sites (e.g., pancreas, liver, kidney, bile duct, salivary and lacrimal glands). ~20K people are diagnosed with IgG4-RD in the US, with similar prevalence rates across geographies. Many patients have some degree of irreversible organ damage at the time of diagnosis. Although nearly all patients initially respond to first line glucocorticoid (GC) therapy, chronic GC therapy is associated with toxicity and relapse is common as patients are tapered off or tapered to low doses.

About Enavate Sciences

Enavate Sciences is a platform created by Patient Square Capital dedicated to supporting therapeutic companies advancing medicines and enabling technologies with transformative potential to address patient need. Through the application of capital support and operational experience, Enavate strives to enable and empower a diverse portfolio of therapeutics companies to accelerate innovation. To learn more about Enavate, please visit www.enavatesciences.com.

About Longitude Capital

Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches. Longitude Capital has offices in Menlo Park, CA, Boston, MA, and Greenwich, CT. For more information, please visit www.longitudecapital.com or LinkedIn.

About Vivo Capital

Founded in 1996, Vivo Capital is a leading global healthcare investment firm with a diverse, multi-fund investment platform in venture capital, growth equity, buyout, and public equities. Vivo has approximately $6.4 billion in assets under management and has invested in over 300 public and private companies worldwide. Headquartered in Palo Alto, California, with additional offices in Asia, the Vivo team consists of more than 50 multi-disciplinary professionals. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets globally.

Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8693158

Over Fifty Leading Chief Executives from Africa take Climate Action at COP27

Over 50 leaders from Africa’s private sector came together at COP27 and with a unified voice, called for accelerated action to build resilience against climate change across the continent.

Sharm El Sheikh, Egypt, Nov. 09, 2022 (GLOBE NEWSWIRE) — At the UN Climate Change Conference (COP27) in Sharm El Sheikh, over 50 leading CEOs from across the African continent who are part of the Africa Business Leaders Coalition (ABLC) presented the Africa Business Leaders’ Climate Statement outlining credible corporate commitments and actions anchored in the goals of the Paris Agreement, the Sustainable Development Goals and the UN Global Compact Ten Principles.

Sanda Ojiambo, Assistant Secretary-General; Executive Director & CEO of the UN Global Compact speaking during the event Climate Action Now: A Critical Priority for Business Leaders said:

“The African business community is already changing Africa and impacting the world for the better. African companies are strengthening partnerships with critical stakeholders, especially governments, to jumpstart climate action across the continent. The Africa Business Leaders’ Climate Statement, which today has 55 signatories, brings a much-needed perspective and set of commitments to the global climate table. It reflects the strong commitment the ABLC member companies have made to driving sustainability efforts in their businesses and across their value chains and ecosystems.”

The Africa Business Leaders’ Climate Statement outlines key commitments companies can make to galvanize climate action through:

  • Developing robust company resilience plans to improve our adaptive capacity and build systemic resilience
  • Upholding the guiding principles of a just transition as central to all our climate actions and advocacy
  • Setting targets to drastically increase the use of renewables to contribute to the continental goal of 27%
  • Contributing to a global dialogue to advance the understanding of the ‘fair share’ principle.

The Africa Business Leaders’ Climate Statement also calls for action from the global community to:

  • Fulfill and enhance the 100-billion-dollar goal by 2023 at the latest and ensure that at least 50% is invested in adaptation and resilience.
  • Create an enabling environment that facilitates increased access to finance and ensures that African business can leverage global markets.
  • Translate climate plans, such as Nationally Determined Contributions (NDCs) and National Adaptation Plans (NAPs), into pipelines of bankable climate projects.
  • Promote technology and knowledge exchange to make decarbonization and adaptation technologies and knowledge more accessible

The ABLC is a CEO-led initiative arising from the UN Global Compact Africa Strategy 2021–2023. It aims to create a stronger partnership between Africa’s private sector and the UN, in order to advance the 2030 Agenda for Sustainable Development and the African Union Agenda 2063. The Ten Principles of the Global Compact are central tenets of the ABLC. The companies that make up the ABLC constitute a genuine pan-African voice with a clear potential to galvanize resources and action by the continent’s private sector. These companies currently represent a total of over one million employees; a combined revenue in excess of US$200 Billion; and a geographical coverage amounting to 93% of the continent.

Notes to Editors 

About the Africa Business Leaders Coalition

The Africa Business Leaders Coalition (ABLC) is a CEO-led initiative emanating from the UN Global Compact Africa Strategy 2021–2023 committed to advancing sustainable growth, prosperity, and development in Africa by bringing measurable impact to its most pressing issues. The ABLC works closely with the UN Global Compact Hub in Abuja and 10 African Local Networks operating across Africa.

About the United Nations Global Compact

As a special initiative of the UN Secretary-General, the United Nations Global Compact is a call to companies everywhere to align their operations and strategies with Ten Principles in the areas of human rights, labour, environment and anti-corruption. Our ambition is to accelerate and scale the global collective impact of business by upholding the Ten Principles and delivering the Sustainable Development Goals through accountable companies and ecosystems that enable change. With more than 15,000 companies and 3,000 non-business signatories based in over 160 countries, and 69 Local Networks, the UN Global Compact is the world’s largest corporate sustainability initiative — one Global Compact uniting business for a better world.

For more information, follow @globalcompact on social media and visit our website at unglobalcompact.org

Media Contact

Alex Gee
gee@unglobalcompact.org

United Nations Global Compact
(212) 907-1301
media@unglobalcompact.org

GlobeNewswire Distribution ID 8693154

Zenas BioPharma ได้รับเงิน 118 ล้านดอลลาร์เพื่อพัฒนาแนวทางการรักษาโรคภูมิต้านตนเองในไปป์ไลน์เป็นวงกว้าง

โดยทางบริษัทได้ดำเนินการให้ทุนสนับสนุนโครงการลงทะเบียนระยะที่ 3 ระดับโลกแก่ Obexelimab ซึ่งเป็นแอนติบอดีที่ได้รับเลือกให้เป็นผลิตภัณฑ์หลักของบริษัทและสนับสนุนการพัฒนาทางคลินิกของโครงการไปป์ไลน์อื่น ๆ

การจัดหาเงินทุน Series B นำโดย Enavate Sciences ซึ่งเป็นบริษัทในเครือของ Patient Square Capital รวมถึงนักลงทุนรายใหม่ซึ่งได้แก่ Longitude Capital และ Vivo Capital

วอลแทม แมสซาชูเซตส์, Nov. 09, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma ในวันนี้ บริษัทชีวเภสัชภัณฑ์ระดับโลกซึ่งมุ่งมั่นที่จะเป็นผู้นำในการพัฒนาและจำหน่ายการรักษาด้วยภูมิคุ้มกันบำบัดในเชิงพาณิชย์นั้น ได้ประกาศถึงรายได้ 118 ล้านดอลลาร์ที่เกี่ยวข้องกับการออกหุ้นบุริมสิทธิ Series B นอกจาก Enavate Sciences ซึ่งเป็นผู้นำด้านการจัดหาเงินทุน Series B แล้ว ก็ยังมีผู้ถือหุ้น Zenas รายใหม่ซึ่งได้แก่ Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners และ Superstring Capital ในส่วนของนักลงทุนรายเดิมที่เคยลงทุนอยู่ไม่ว่าจะเป็น Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund และ Xencor, Inc. ก็เข้าร่วมในการจัดหาเงินทุนด้วย ซึ่งการจัดหาทุนนี้ได้รวมถึงการเพิ่มทุนใหม่ ตลอดจนการแปลงหุ้นกู้แปลงสภาพที่ออกให้แก่นักลงทุนบางรายล่วงหน้าการปิดการจัดหาเงินทุน Series B

รายได้จากการจัดหาเงินทุนจะช่วยในการสนับสนุนความก้าวหน้าทางคลินิกของ Obexelimab ซึ่งเป็นแอนติบอดีที่ได้รับเลือกให้เป็นผลิตภัณฑ์หลักของบริษัท โดยการสนับสนุนนี้จะครอบคลุมถึงการทดลองลงทะเบียนระยะที่ 3 ระดับโลกของผู้ป่วยในโรคที่เกี่ยวข้องกับ IgG4 (IgG4-RD) โดยระยะนี้จะเริ่มต้นในปลายปี 2022 นอกจากนี้ การระดมทุนครั้งใหม่จะทำให้โครงการที่เกี่ยวกับโรคภูมิต้านตนเองอื่น ๆ ในระดับโลกของบริษัทก้าวหน้าไปสู่การพัฒนาทางคลินิกในปี 2023 อีกด้วย

“ทางเรารู้สึกตื่นเต้นมากครับที่ได้สนับสนุน Zenas ในฐานะผู้นำด้านนวัตกรรมด้านเทคโนโลยีชีวภาพ ในขณะที่ทางทีมงานก็ได้ดำเนินการตามแผนพัฒนาทางคลินิกสำหรับ IgG4-RD และไปป์ไลน์ที่มีประสิทธิภาพของการรักษาด้วยภูมิคุ้มกันบำบัดที่ได้มาอย่างเชี่ยวชาญผ่านการพัฒนาธุรกิจเชิงกลยุทธ์ เราเชื่อว่า Zenas จะประสบความสำเร็จในการจำหน่ายนวัตกรรมการรักษาเพื่อปรับปรุงชีวิตของผู้ที่เผชิญกับโรคภูมิต้านตนเองและโรคที่พบได้ยาก” James Boylan ประธานเจ้าหน้าที่บริหารของ Enavate Sciences กล่าว

Lonnie Moulder ผู้ก่อตั้งและประธานกรรมการบริหารของ Zenas BioPharma กล่าวว่า “เรารู้สึกตื่นเต้นที่ได้รับการสนับสนุนจาก Enavate และกลุ่มนักลงทุนชั้นนำระดับโลก ในขณะที่เราเองก็ยังคงเดินหน้าพัฒนาไปป์ไลน์ของการรักษาโรคภูมิต้านตนเองในขณะมีอาการของโรคได้อย่างลึกซึ้งและสมดุล อีกทั้งดำเนินกลยุทธ์การพัฒนาธุรกิจที่ประสบความสำเร็จของเราควบคู่ไปด้วย”

Jim Boylan CEO ของ Enavate Sciences, Patrick Enright ผู้ร่วมก่อตั้งและกรรมการผู้จัดการของ Longitude Capital และ Hongbo Lu หุ้นส่วนผู้จัดการของ Vivo Capital ได้เข้าร่วมคณะกรรมการบริหารของ Zenas ซึ่งพวกเขาทั้งหมดเกี่ยวข้องกับการจัดหาเงินทุน Series B

เกี่ยวกับ Zenas BioPharma

Zenas BioPharma เป็นบริษัทชีวเภสัชภัณฑ์ระดับโลกที่มุ่งมั่นที่จะเป็นผู้นำในการพัฒนาและจำหน่ายการรักษาด้วยภูมิคุ้มกันบำบัดให้แก่ผู้ป่วยทั่วโลก Zenas กำลังพัฒนาการรักษาโรคภูมิต้านตนเองในขณะมีอาการของโรคอย่างลึกซึ้งและสมดุลด้วยการพัฒนาทางคลินิกและการปฏิบัติการทั่วโลก ซึ่งเป็นไปได้ว่านี่อาจจะเป็นการรักษาใหม่และที่ดีที่สุดก็ว่าได้ การรักษานี้ได้รักษาในส่วนพื้นที่ที่มีความต้องการทางการแพทย์ที่ไม่ได้รับการตอบสนองสูง ควบคู่ไปกับการปฏิบัติตามข้อกำหนดด้านคุณค่าของสภาพแวดล้อมการดูแลสุขภาพแบบไดนามิกระดับโลก ไปป์ไลน์ของบริษัทเติบโตอย่างต่อเนื่องผ่านกลยุทธ์การพัฒนาธุรกิจที่ประสบความสำเร็จของเรา ทีมผู้นำที่มีประสบการณ์และเครือข่ายพันธมิตรทางธุรกิจของเราขับเคลื่อนความเป็นเลิศในการดำเนินงานเพื่อส่งมอบการบำบัดต่าง ๆ ที่มีความเป็นไปได้ที่จะก่อให้เกิดการปลี่ยนแปลงได้ ทั้งนี้ก็เพื่อที่จะปรับปรุงชีวิตของผู้ที่เผชิญกับโรคภูมิต้านทานตนเองและโรคที่พบได้ยากต่าง ๆ ให้ดีขึ้น สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Zenas BioPharma โปรดไปที่ www.zenasbio.com และติดตามพวกเราบน Twitter ได้ที่ @ZenasBioPharma และ LinkedIn

เกี่ยวกับ Obexelimab

Obexelimab (ZB012) เป็นแอนติบอดีแบบโนเวลไบฟังก์ชันระยะสอบสวนใหม่ที่ 3 ซึ่งเป็นแอนติบอดีตัวแรกที่มีศักยภาพในการยับยั้งการสืบเชื้อสายของบีเซลล์ที่แสดง CD19 การจับพร้อมกันกับ CD19 และ Fc.RIIB โดย obexelimab นั้นจะเลียนแบบคอมเพล็กซ์แอนติเจนและแอนติบอดีตามธรรมชาติและควบคุมการทำงานของเซลล์บี ในการศึกษาทางคลินิกในระยะเริ่มต้น obexelimab แสดงให้เห็นถึงการยับยั้งการทำงานของเซลล์บีได้อย่างมีประสิทธิภาพโดยไม่ทำลายเซลล์ และสร้างผลการรักษาที่ช่วยให้กำลังใจในผู้ป่วยโรคภูมิต้านตนเองหลายชนิด Zenas ได้รับสิทธิในแอนติบอดี obexelimab จาก Xencor, Inc. แต่เพียงผู้เดียว

เกี่ยวกับ IgG4-RD

IgG4-RD เป็นโรคที่มีการอักเสบเรื้อรังและร้ายแรง ซึ่งมักส่งผลกระทบต่ออวัยวะและตำแหน่งต่าง ๆ (เช่น ตับอ่อน ตับ ไต ท่อน้ำดี ต่อมน้ำลาย และต่อมน้ำตา) มีประชากรประมาณ 20,000 คนที่ได้รับการวินิจฉัยว่าเป็น IgG4-RD ในสหรัฐอเมริกา โดยมีอัตราความชุกใกล้เคียงกันทั่วทุกภูมิภาค ในขณะที่ทำการวินิจฉัยนั้น พบว่ามีผู้ป่วยจำนวนมากมีความเสียหายในส่วนของอวัยวะที่ไม่สามารถกลับคืนสู่สภาพปกติได้ในระดับหนึ่ง แม้ว่าผู้ป่วยเกือบทั้งหมดในขั้นต้นจะตอบสนองต่อการรักษาด้วยยา glucocorticoid (GC) ในขั้นตอนแรก แต่การบำบัดด้วย GC แบบยาวนานนั้นสัมพันธ์กับความเป็นพิษและการกำเริบอีกนั้นพบได้บ่อย เนื่องจากผู้ป่วยลดขนาดยาลงหรือลดขนาดยาให้เหลือเพียงขนาดต่ำ

เกี่ยวกับ Enavate Sciences

Enavate Sciences เป็นแพลตฟอร์มที่สร้างขึ้นโดย Patient Square Capital เพื่อสนับสนุนบริษัทด้านการรักษาที่พัฒนายาและใช้เทคโนโลยีที่มีศักยภาพในการเปลี่ยนแปลงเพื่อตอบสนองความต้องการของผู้ป่วย Enavate มุ่งมั่นที่จะเปิดทางและส่งเสริมกลุ่มบริษัทด้านการรักษาที่หลากหลายเพื่อเร่งสร้างนวัตกรรม ด้วยการใช้เงินทุนสนับสนุนและประสบการณ์ในการดำเนินงาน หากต้องการเรียนรู้เพิ่มเติมเกี่ยวกับ Enavate กรุณาเยี่ยมชม www.enavatesciences.com

เกี่ยวกับ Longitude Capital

Longitude Capital เป็นบริษัทร่วมทุนด้านการดูแลสุขภาพชั้นนำที่ลงทุนในบริษัทด้านเทคโนโลยีชีวภาพ เทคโนโลยีทางการแพทย์ และโซลูชันด้านสุขภาพที่มีการปรับปรุงเปลี่ยนแปลง ซึ่งมีเป้าหมายในการแสวงหาการปรับปรุงผลลัพธ์ทางคลินิก ยกระดับคุณภาพชีวิต และขับเคลื่อนประสิทธิภาพของการส่งมอบบริการด้านสุขภาพ Longitude Capital ก่อตั้งขึ้นในปี 2006 โดยทางบริษัทได้ลงทุนในทั้งบริษัทเอกชนและบริษัทที่ซื้อขายในตลาดหลักทรัพย์ผ่านแนวทางการลงทุนที่หลากหลาย Longitude Capital มีสำนักงานอยู่ใน เมนโลพาร์ก แคลิฟอร์เนีย บอสตัน แมสซาชูเซตส์ และ กรีนิช คอนเนตทิคัต สำหรับรายละเอียดเพิ่มเติม กรุณาเยี่ยมชม www.longitudecapital.com หรือ LinkedIn.

เกี่ยวกับ Vivo Capital

Vivo Capital ก่อตั้งขึ้นในปี 1996 เป็นบริษัทด้านการลงทุนด้านการดูแลสุขภาพชั้นนำระดับโลกด้วยแพลตฟอร์มการลงทุนแบบหลายกองทุนที่มีความหลากหลายไม่ว่าจะเป็นธุรกิจเงินร่วมลงทุน หุ้นเติบโต การซื้อขายหุ้นของบริษัท และหุ้นสาธารณะ Vivo มีสินทรัพย์ภายใต้การบริหารประมาณ 6.4 พันล้านดอลลาร์ และได้ลงทุนในบริษัทภาครัฐและเอกชนกว่า 300 แห่งทั่วโลก สำนักงานใหญ่ของ Vivo ตั้งอยู่ในเมืองพาโลอัลโต แคลิฟอร์เนีย และมีสำนักงานเพิ่มเติมในเอเชียอีกหลายแห่ง โดยทีม Vivo นั้นประกอบด้วยผู้เชี่ยวชาญจากหลากหลายสาขามากกว่า 50 คน Vivo ลงทุนในทุกกลยุทธ์ของกองทุน โดยลงทุนในด้านการดูแลสุขภาพอย่างกว้างขวาง ซึ่งรวมถึงเทคโนโลยีชีวภาพ ยา อุปกรณ์ทางการแพทย์ และบริการด้านสุขภาพ โดยมุ่งเน้นที่ตลาดการดูแลสุขภาพที่ใหญ่ที่สุดในโลก

ช่องทางติดต่อสำหรับนักลงทุนและสื่อ:
Joe Farmer ประธานบริษัทและประธานเจ้าหน้าที่ฝ่ายปฏิบัติการ
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8693127

Citeline and EMIS Partner to Expand Clinical Trial Access in the UK

New alliance will boost access to clinical trials for thousands of individuals in the UK through their clinicians

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) — EMIS, the leading provider of healthcare software, information technology and related services in the UK, and Citeline Connect, the most comprehensive solution for clinical trial engagement and recruitment, today announced a strategic partnership to make clinical trials more accessible to patient populations throughout the UK.

This relationship will allow EMIS to better serve its communities by providing direct, immediate opportunities for eligible patients to participate in clinical trials. EMIS Group’s Recruit product will notify clinicians when new opportunities arise for their patients to consider and enroll in clinical trials as a care option. EMIS Recruit uses advanced analytics and algorithms powered by EMIS-X to identify eligible patients.

“We are excited at this tremendous opportunity to open clinical research opportunities to patients throughout the UK and support clinical trial diversity efforts,” said Suzy Foster, CEO of EMIS Health and EMIS Enterprise. “This innovative collaboration between EMIS Group and Citeline Connect has potential to change patients’ lives and advance healthcare.”

Citeline Connect is a comprehensive platform and marketplace that powers smarter, simpler patient referrals for clinical trials with HIPAA, GDPR-compliant technology. It enables clinical trial sponsors to securely share recruitment opportunities with a vetted network of patient recruitment companies, healthcare organizations, and patient advocacy groups. Citeline Connect bridges the gap between Citeline-coordinated clinical trials in search of patients and healthcare organizations with patients looking for promising potential solutions for the management of their conditions.

“EMIS’s infrastructure underpins most of the UK health system, and their reach into healthcare professionals and patients throughout the UK is unmatched,” says Ashley Schwalje, Head of Commercialization at Citeline Connect. “Speaking on behalf of the entire leadership team at Citeline, we couldn’t be more thrilled to welcome EMIS into the Citeline Connect community.”

About EMIS

EMIS is the UK leader in connected healthcare software and systems. Its solutions are widely used across every major UK healthcare setting. EMIS’s aim is to be the leading provider of innovative healthcare technology that improves people’s lives. This helps healthcare professionals to deliver better, more efficient healthcare, supporting longer and healthier lives.

EMIS has two core business segments: EMIS Health and EMIS Enterprise.

About Citeline Connect

Citeline Connect is the most comprehensive solution for clinical trial engagement and recruitment. This solution revolutionizes how patients find and enroll in clinical research across the globe by combining the power of data-driven technology with the reach of proprietary HCP networks and 85+ pre-vetted partners from an industry-first patient referral collective. For more information, visit CitelineConnect.com.

Media Contacts

EMIS Group
emis@weareic.com

Citeline PR
citelineuk@diffusionpr.com

GlobeNewswire Distribution ID 8692356

TIS Launches FX Payment Service Across 175+ Countries With 140+ Currency Options

Offering Significantly Reduces Cross-Border Payment Costs for Global Organizations

Featured Image for TIS

Featured Image for TIS

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) — Today, enterprise payments leader Treasury Intelligence Solutions (TIS) announced the launch of their global FX payment service, which provides multinational clients with in-platform access to over 140 currency options across 175+ countries.

By using TIS’ platform to execute cross-border transactions, companies can avoid the expensive FX fees and non-competitive exchange rates that are often observed in the market. As a result, companies that generate a high volume of cross-border transactions can achieve significant cost savings.

Due to the increasingly global nature of modern business and the need for organizations to execute payments across numerous regions and territories, the new suite of FX payment services offered by TIS provides immense value. The primary benefits afforded to organizations include:

  • Integrated Access to 140+ Currencies Across 175+ Countries. TIS’ FX payment capabilities provide businesses with integrated access to nearly every currency option and local market in the world.
  • Reduced FX Rates & Transaction Fees. With the ability to execute cross-border payments using local currencies and payment rails, TIS users can achieve significantly lower FX rates and transaction fees compared to traditional channels. Pricing is competitive and transparent.
  • Secure & Seamless Cash & Currency Management. When combined with TIS’ existing suite of payments and liquidity management solutions, businesses can now improve their level of security, enhance process efficiency, and gain complete control over their global cash and payments activity across any bank, region, entity, currency, network, or market.

As of November 2022, TIS clients, including award-winning Non-Profit IFAW, were already leveraging the FX payment solution to achieve substantial cost savings over their previous setup. According to John Kluza, Group Treasurer at IFAW, “For several years now, we have been using TIS to manage global bank connectivity and payment workflows across 20+ banks and 40+ countries. Now with their integrated FX payment tools, IFAW can enhance our cross-border payments activity to incur less fees in each region we service. So far, we have been very satisfied with the results.”

This sentiment was backed by Joerg Wiemer, Co-Founder and CSO of TIS, who said, “Many TIS clients are multinational organizations that stand to benefit significantly from enhanced FX payment solutions. With these new capabilities, TIS now provides market-leading FX payment services that enable clients to substantially reduce their cross-border payment fees and also exercise more control over global payment operations, especially when transacting in foreign markets.”

Download the expanded factsheet FX Payment Management.

About TIS

TIS helps organizations simplify and streamline their global payments and liquidity management operations. Our cloud-based platform empowers businesses to optimize critical functions surrounding cross-border and domestic payments, bank connectivity, cash forecasting, fraud prevention, payment compliance, and more. Corporations, institutions, and business vendors leverage TIS to transform how they connect with global banks and financial systems, collaborate on payment processes, execute outbound payments, analyze cash flow & compliance data, and promote working capital efficiency.

Visit tispayments.com

Contact Information:
Jennifer Knutel
VP Marketing
jennifer.knutel@tispayments.com
978-875-2085

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Attachment

GlobeNewswire Distribution ID 8692243

Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022

– BPT567, a first-in-class PD1-IL18 immunocytokine, delivers coordinated PD-1 blockade and potent IL-18 signaling to PD-1+ T effector cells resulting in striking antitumor activity –

– BPT331, a PD1-IL2 cis-signaling immunocytokine with potent best-in-class properties –

– Innovative chemical conjugation platform enables combination of multiple key immuno-oncology mechanisms in a single molecule with unparalleled flexibility –

SAN DIEGO and BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a privately held biotechnology company developing next-generation, multifunctional precision immunotherapies for cancer and autoimmune disease, today announced the presentation of multiple new cancer immunotherapy agents at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held on November 9-12, 2022, in Boston, MA.

Bright Peak has leveraged its exclusive technology platform and world-class protein engineering capabilities to functionally optimize the master cytokines IL-18 and IL-2, and integrated these highly active payloads with PD-1 checkpoint blockade. “We are extremely excited to present our PD-1-targeted multifunctional immunocytokines. We are advancing these therapeutics to upgrade immune checkpoint therapy to the next level – our aim is to establish these unique “PD-1 2.0” programs as new backbone agents in immuno-oncology,” said Jon Wigginton M.D., President of Research and Development of Bright Peak Therapeutics. “At SITC, we are introducing BPT567, the first ever PD1-IL18 immunocytokine. We have observed compelling preclinical antitumor activity with BPT567. We hypothesize that BPT567 may accomplish this by simultaneously blocking the PD-(L)1 pathway and delivering strong IL-18 signaling in cis to PD-1+ IL18R+ T effector (Teff) cells located within the tumor microenvironment.”

Additionally, using the same functionally optimized IL-18 payload that has been incorporated into BPT567, Bright Peak has developed BPT543, a best-in-class, half-life extended IL-18 therapeutic designed for IV administration. This IL-18 binding protein-resistant molecule with enhanced affinity for the IL-18 receptor has demonstrated striking synergistic antitumor activity in combination with PD-1 blockade in preclinical models.

“We have also advanced BPT331, a PD1-IL2 immunocytokine that demonstrates superior antitumor activity compared to PD-1 inhibition alone,” continued Dr. Wigginton. “We rationally designed our PD-1 targeted IL-2 payload with the intent of selectively targeting and activating antigen-experienced PD-1+ Teff cells in the tumor microenvironment, while limiting the broad systemic activation of other immune cells.”

Details regarding the upcoming SITC abstract presentations are as follows:

November 10, 2022, 9:00 AM – 9:00 PM (EST)
Poster 1195: Generation of a highly potent, cis-signaling PD1-IL2 immunocytokine using a novel chemical synthesis and conjugation platform

Abstract Highlights: Bright Peak has developed a unique, chemical conjugation process that enables the generation of immunocytokines via rapid and site-specific conjugation of synthetically engineered cytokines to the Fc domain of existing human Abs. We generated a PD1-IL2 immunocytokine (BPT331) with significantly enhanced potency in PD-1high versus PD-1low T cells. In mice, high tumor exposure of BPT331 relative to blood combined with PD-1-targeting and cis-signaling result in potent immune stimulation, and strong antitumor efficacy that is markedly superior to an anti-PD-1 antibody alone. These results demonstrate the ability of our cytokine engineering platform to generate potent, multifunctional immunocytokine therapeutics with synergistic, complementary mechanisms of action.

November 11, 2022, 9:00 AM – 8:30 PM (EST)
Poster 1080: Using site-specific chemical conjugation to generate superior half-life extended or PD-1-targeted formats of a potent IL-18 variant resistant to IL-18 binding protein

Abstract Highlights: Bright Peak has identified a conjugatable variant of human IL-18 that is 300-fold more potent and >600-fold less sensitive to inhibition by its natural inhibitor IL-18 binding protein (IL-18BP) than wild-type IL-18. Site-specific conjugation of this enhanced IL-18 payload to a 30 kDa PEG created BPT543, which significantly improves PK/PD properties, and mediates strong antitumor efficacy and potent synergy in combination with an anti-PD-1 antibody. Chemical conjugation of our enhanced IL-18 payload to an anti-PD-1 antibody generated BPT567, a PD1-IL18 immunocytokine with fully preserved potency of the cytokine payload as well as PD-1 binding. BPT567 demonstrates enhanced potency in PD-1high versus PD-1low T cells, and exhibits striking antitumor activity in vivo, with complete responses in 89% of animals.

The abstracts will be made available for viewing on Bright Peak’s website upon presentation at the SITC Annual Meeting (www.brightpeaktx.com).

About Bright Peak Therapeutics

Bright Peak is a privately held biotechnology company based in Basel, Switzerland and San Diego, CA. We are rapidly advancing a robust portfolio of next generation, multifunctional, immunotherapies for the treatment of patients with cancer and autoimmune disease. We accomplish this by leveraging our world class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. Our pipeline stretches from discovery to IND-enabling and encompasses enhanced cytokines, antibody-cytokine conjugates and other novel formats. Bright Peak is funded by a syndicate of leading healthcare investors.

Contact: info@brightpeaktx.com

GlobeNewswire Distribution ID 8692514

Hitachi Energy to provide world’s first SF6-free 420 kV gas-insulated switchgear technology at TenneT’s grid connection in Germany

Contributing to TenneT’s carbon neutrality goals to build a sustainable and resilient grid in Germany

Zurich, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) — Hitachi Energy announced today it will provide the world’s first sulfur hexafluoride (SF6) free 420-kilovolt (kV) gas-insulated switchgear (GIS) technology and a state-of-the-art modular prefabricated grid connection solution at a key node at TenneT’s power grid in Germany, supporting the leading European grid operator to achieve its carbon neutrality goals.

This project covers a major grid connection upgrade which significantly extends the operating life of existing power assets to ensure the longevity and continued efficiency of the existing power infrastructure. The global technology leader will deliver innovative EconiQ™ 420 kV GIS that uses a game-changing technology that eliminates SF6 with reliable and scalable solutions for the lowest carbon footprint.

TenneT is a major transmission system operator in the Netherlands and Germany, supplying power to some 42 million homes and businesses in both countries. The company aims to be a driving force behind the energy transition by investing in eco-efficient technologies to reduce greenhouse gas emissions. As a transmission system operator, TenneT is a key player on the historic path to a safe, reliable and carbon-free energy system.

To support TenneT on its transition to SF6-free solutions, Hitachi Energy will contribute pioneering technologies, unique system integration capabilities, engineering expertise and extensive experience with local grid code requirements to strengthen the grid connection at the 220-megawatt (MW) Erzhausen pumped storage power plant near Hanover. This project uses Building Information Modeling, a consolidated and collaborative digital working method that allows decision-based 3D modeling and improves facility management via a digital twin for the life cycle of the power asset. The entire project will be completed in 2026.

In this project, Hitachi Energy will install three bays of EconiQ 420 kV GIS to enable the transmission of large amounts of electricity over long distances while eliminating significant volumes of SF6. This eco-efficient innovation remains similar in size while being 100 percent as reliable as the conventional GIS solution based on SF6. This installation will effectively avoid the addition of nearly 2,300 kg of SF6, equivalent to removing the CO2 emissions of around 1,1501 passenger vehicles per year.

“We are proud to collaborate with TenneT in their efforts to accelerate the energy transition and strengthen the power infrastructure in Germany,” said Claudio Facchin, Chief Executive Officer of Hitachi Energy. “At Hitachi Energy, we are championing the urgency of the energy transition through innovation and collaboration. Through our modular prefabricated grid connections and EconiQ high-voltage switchgear technology, we are supporting our customers to reduce their carbon footprint and enabling a more sustainable, flexible and secure energy system.”

EconiQ is Hitachi Energy’s eco-efficient portfolio for sustainability, where products, services and solutions are proven to deliver exceptional environmental performance. Hitachi Energy has placed sustainability at the heart of its Purpose and is advancing a sustainable energy future for all.

1 Based on the assumption that a passenger vehicle emits 19 kg CO2 equivalent per 100 km and drives 10,000 km per year.

About Hitachi Energy Ltd.

Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world’s energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. Headquartered in Switzerland, we employ around 40,000 people in 90 countries and generate business volumes of approximately $10 billion USD.

https://www.hitachienergy.com

https://www.linkedin.com/company/hitachienergy

https://twitter.com/HitachiEnergy

About Hitachi, Ltd.

Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company’s consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.

Attachments

Jocelyn Chang
Hitachi Energy Ltd.
+41793847775
jocelyn.chang@hitachienergy.com

GlobeNewswire Distribution ID 8692688

Sacombank Selects Temenos Infinity to Elevate Digital Banking and Deliver Seamless Omnichannel Experience

Leading Vietnam bank will use Temenos to power digital banking for over 15 million retail and business customers

Sacombank and Temenos Signing Ceremony for Omnichannel Banking Platform Implementation

[Front row left to right]: Craig Bennett, Managing Director – APAC, Temenos; Bui Van Dung, Deputy CEO, Sacombank; Pham Dang, Deputy CEO, HiPT.

GENEVA, Nov. 09, 2022 (GLOBE NEWSWIRE) —  Temenos (SIX: TEMN), today announced that Sacombank, one of the largest banks in Vietnam with over 15 million customers, has selected Temenos Infinity to elevate its digital banking and deliver a seamless omnichannel experience to retail and business customers.

Since Kony’s acquisition in 2019, Temenos Infinity has been selected by over 200 new customers and the product’s leadership has been cemented with multiple analyst accolades. Temenos has been named a leader in the Forrester Waves™Digital Banking Engagement Platforms and Digital Banking Engagement Hubs evaluations in 2021. Temenos was also the only vendor rated best-in-class in Aite Matrix Evaluation of US digital banking solutions.

Sacombank has a customer-centric business strategy focused on providing high-quality financial products and services to individual and corporate customers, especially small and medium-sized enterprises. Temenos Infinity will enable the bank to reimagine the way it interacts with customers and meet the growing customer demand for digital products and services and fast, frictionless customer experiences.

Vietnam is leading the way in digital banking in Southeast Asia. It has a large younger demographic of digitally savvy consumers and a vibrant local fintech and ecommerce industry. Vietnamese enjoy quick and easy digital experiences for a wide variety of services and expect the same from their banking.

Temenos Infinity is a true omnichannel, multi experience platform-based product that enables a comprehensive 360-degree customer view, helping Sacombank to acquire, service, retain and cross-sell to customers, on multiple channels and devices using native features. Offering pre-composable banking services – built on microservices and accessible via APIs – the platform enables Sacombank to develop innovative products quickly and that bring real benefits to consumers and businesses.

The bank plans to introduce fully digital customer onboarding and origination as well as enhance the service experience for existing customers through digital channels. Additionally, Temenos’ open and composable platform will help Sacombank connect with e-commerce providers, social networks and other online services to accelerate a cashless ecosystem, a priority for the Government of Vietnam.

In selecting a new digital banking platform, Sacombank looked at various leading solutions in the market and after a thorough evaluation decided on Temenos Infinity. Sacombank is a longstanding Temenos customer and will run Temenos Infinity on top of its existing Temenos Transact core, providing complete front-to-back banking capabilities on a single platform.

Temenos Infinity is the world’s best-selling digital banking platform used by over 850 financial institutions, from global tier one banks to digital challengers. It can connect to any core banking system as a standalone solution for larger banks or to Temenos Transact. Temenos Infinity can run on any cloud or as SaaS on the Temenos Banking Cloud.

Bui Van Dung (Mr.), Deputy CEO, Sacombank said: “The omnichannel platform project is an unavoidable step to make a breakthrough in digital business of Sacombank. Sacombank believes that Temenos has the best reputation, capacity, and technology in omnichannel, along with a consultant team experienced in implementing similar projects at the leading banks, financial institutions in area and world-wide, hence, Temenos is able to support Sacombank in implementing its digital business strategy to comprehensively innovate in quality.”

Craig Bennett, Managing Director – APAC, Temenos, said: “Vietnam is a strategic market for Temenos. More than 20 Vietnamese banks run on our core banking technology, and we see growing adoption and interest for our Temenos Infinity digital banking platform. As one of the biggest banks in Vietnam and the Southeast Asia region, we are hugely proud to extend our relationship with Sacombank. Adding Temenos Infinity to the bank’s technology stack will propel the bank forward, opening new opportunities and delivering outstanding customer experiences.”

About Temenos
Temenos (SIX: TEMN) is the world’s leading open platform for composable banking, creating opportunities for over 1.2 billion people around the world every day. We serve over 3000 banks from the largest to challengers and community banks in 150+ countries by helping them build new banking services and state-of-the-art customer experiences. The Temenos open platform helps our top-performing clients achieve return on equity three times the industry average and cost-to-income ratios half the industry average.

For more information, please visit www.temenos.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/54af5e1a-1e98-4441-897e-7d90b91e8ad4

Media Contacts

 
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email: press@temenos.com

Alistair Kellie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com

GlobeNewswire Distribution ID 8692708